The 5-HT₂C receptor agonist, lorcaserin, and the 5-HT₆ receptor antagonist, SB-742457, promote satiety; a microstructural analysis of feeding behaviour.
BACKGROUND
Whilst the FDA-approved anorectic, lorcaserin and various 5-hydroxytryptamine (5-HT)6 receptor antagonists reduce feeding, a direct assessment of their impact upon feeding behaviour is less clear. We therefore examined the action of lorcaserin and the clinical-stage developmental candidate 5-HT6 receptor antagonist, SB-742457, upon microstructural analysis of licking behaviour. Such analysis provides a rich source of information about the mechanisms controlling food intake.


OBJECTIVE
The objective of the present study was to gain insight into the influence upon feeding behaviour of the 5-HT2C receptor agonist, lorcaserin and the developmental 5-HT6 receptor antagonist, SB-742457.


METHODS
The impact of lorcaserin and SB-742457 upon licking behaviour of non-deprived rats for a glucose solution was assessed using microstructural analysis.


RESULTS
Lorcaserin (0.1-3.0 mg/kg) displayed a dose-dependent ability to reduce glucose consumption via reduction in the number of bouts of licking. A similar action was evident with SB-742457, but only at the lowest dose tested (3.0 mg/kg).


CONCLUSIONS
The behavioural actions of both lorcaserin and SB-742457 demonstrate they directly promote satiety.
School of Psychology, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK.
Suzanne
S
Higgs
School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK.
Alison J
AJ
Cooper
School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK. n.m.barnes@bham.ac.uk.
Nicholas M
NM
Barnes
D000818:Animals; D001552:Benzazepines / Q000494:pharmacology*; D003216:Conditioning, Operant / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D005247:Feeding Behavior / Q000187:drug effects*; D005947:Glucose / Q000494:pharmacology; D008297:Male; D011804:Quinolines / Q000494:pharmacology*; D051381:Rats; D044405:Receptor, Serotonin, 5-HT2C / Q000187:drug effects*; D011985:Receptors, Serotonin / Q000187:drug effects*; D012528:Satiety Response / Q000187:drug effects*; D058826:Serotonin 5-HT2 Receptor Agonists / Q000494:pharmacology*; D012702:Serotonin Antagonists / Q000494:pharmacology*; D013450:Sulfones / Q000494:pharmacology*
C548140:3-benzenesulfonyl-8-piperazin-1-ylquinoline; D001552:Benzazepines; D011804:Quinolines; D044405:Receptor, Serotonin, 5-HT2C; D011985:Receptors, Serotonin; D058826:Serotonin 5-HT2 Receptor Agonists; D012702:Serotonin Antagonists; D013450:Sulfones; C097216:serotonin 6 receptor; C506658:lorcaserin; D005947:Glucose
5-HT2C receptor; 5-HT6 receptor; Feeding behaviour; Lorcaserin; Microstructural analysis; Obesity